Daewoong Pharma reports 104 patients enrolled in Phase 2 IPF trial of Bersiporocin
Daewoong Pharma presented baseline data for 104 patients in a global Phase 2 trial of IPF candidate bersiporocin at ERS 2026. The study is designed to test the drug in patients already on standard antifibrotic therapy, as well as those not receiving it. Enrollment is complete in the US and South Korea, positioning the